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Abstract 
Aims: This study explored family physicians’ (FPs) stated practices and decision-making 
for lung cancer screening.  
Methods: Cross-sectional survey of a stratified random sample of Saskatchewan FPs 
using single item questions and simulated clinical scenarios. 
Findings: Wide variations in FPs’ lung cancer screening practices exist in their decision 
to screen and choice of screening test. Certain physician, patient and non-medical factors 
influence FPs’ decision-making contrary to their perception of guidelines.  
Conclusions:  The high self-reported prevalence and measured inclination to screen in 
clinical scenarios contrary to prevailing guidelines adds unnecessary health care costs and 
has potential to cause harm. 
Significance: First and unique study regarding lung cancer screening in family practice 
in Canada. It contributes to the literature about existing FP practices and decision-making 
regarding lung cancer screening and highlights implications to health care cost, patient 
care and CME initiatives. 
Keywords: Lung Cancer Screening, Decision-making, Clinical Practice Guidelines, 
Family Medicine. 
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1.1 Chapter Overview 
This chapter describes the significance of lung cancer, guidelines, decision-making and 
practice variations in behaviour of family physicians (FPs) regarding lung cancer 
screening. The literature reports variation in medical practice that is not based on 
carefully constructed guidelines. This variation is seen in procedures where evidence is 
unclear or conflicting as well as where there is a clear consensus in guidelines.1 Factors 
such as anxiety about cancer and expectation expressed by patients for a screening test 
influence FPs to order screening tests.2  
The decision-making context in which screening decisions are made is explored. Issues 
about screening and guidelines are highlighted; physician’s attitude towards screening in 
general, cancer screening, lung cancer screening, use of guidelines and variation in their 
practice behaviour are presented.  
The variation in guidelines, risk of lung cancer and limited detection and treatment 
options raise questions about FPs decision-making on lung cancer screening for their 
patients. For example, do they screen for lung cancer? If they do, how often do they 
screen and which screening tests are ordered? Additionally the literature lacks evidence 
on how those decisions are made. Specifically, what factors influence a FP to order or not 
order a screening test for lung cancer? Do patient’s preferences, fears and expectations, 
physician factors and the influence of colleagues, personal experience with cancer and 
availability, access and cost of the screening test influence their decision making for lung 
cancer screening? 
This chapter concludes with a summary, which synthesizes the rationale for research 
based on gaps in knowledge and evidence presented in the literature review. Finally, the 
study research questions are formulated, corresponding research objectives defined and a 
conceptual FP lung cancer screening decision making model introduced. 
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1.2 Literature Review 
1.2.1 Significance of Lung Cancer 
Lung cancer accounts for the highest cancer mortality rate for both men and women 
according to American Cancer Society data.3 The 2011 statistics show it is the leading 
cause of cancer death for men aged 40 and older, and for women aged 60 and older.3 The 
five-year survival rate is only 16%3 and 90% with the disease die from it.4 Smoking is the 
most important risk factor causing 85% of U.S. lung cancer cases.4 The primary reason 
for such a poor cure rate is that nearly all lung cancers are found at a very late stage, 
making curative treatment impossible.5 Even with recent advances in detection, 
“screening cannot prevent most lung-cancer deaths, and smoking cessation remains 
essential.”4, p331 
1.2.2 Lung Cancer Screening 
An editorial on the status of lung cancer screening6 stressed the need for effective clinical 
strategies for aiding patients with lung cancer , which has the highest incidence and 
mortality among  all cancers. Some groups, for example, the US Lung Cancer Alliance, 
advocate use of computed tomography (CT) scan for lung cancer screening. This position 
was clearly against the best available screening guidelines (at the time of the present 
study) which did not recommend (i.e. cited insufficient evidence for or against7 or 
recommended against8) use of CT or chest X-ray (CXR) respectively. Only recently, the 
United States Preventative Services Task Force (USPSTF) 2014 Lung Cancer screening 
recommendation statement4 updated their 2004 recommendation statement7 to 
recommend annual CT Scan for high risk patients. Those at high risk were defined as 
asymptomatic current smokers or those who had quit within the last 15 years, and those 
between the ages of 55 years and 80 years having a 30 pack per year smoking history. 
This guideline was graded as category B meaning “there is high certainty that the net 
benefit is moderate or there is moderate certainty that the net benefit is moderate to 
substantial.”4, Appendix, Table 1 
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The literature reports physician ordering of  CXR as a test for lung cancer screening 
despite the fact that guidelines were against its use.9 It may be the case that certain patient 
factors, such as patient anxiety, diagnosis, or death in close friend or family member, and 
patient demands play a vital role in the final decision to order or not order a screening test 
for lung cancer.  
Research is required to study the behaviour of FPs regarding lung cancer screening and to 
explore what factors influence their decision- making. Factors influencing decision 
making for cancer screening  indicate physician factors, patient factors, and patient-
physician relationship are key to finding common ground and lead toward a mutual 
decision on whether or not to screen for several cancers.10 However, this model emerged 
from studying cancer screening decision-making for cancers such as prostate, colorectal 
and breast cancer but did not study lung cancer decision making. The goal of that study 
was to understand the decision making process for cancers where National Guidelines 
from two or more sources are different.  
One study9 utilized a survey questionnaire to explore attitudes, beliefs and behaviours on 
lung cancer screening. The researchers concluded that a substantial number of physicians 
screen for lung cancer using CXR (25%) despite the fact that it was not recommended. 
They also discovered that pulmonologists screen more than family practitioners and those 
with more years in practice screen more frequently than those with fewer years in 
practice.9  Further research is required to identify the factors that influence decision- 
making for lung cancer screening. 
Screening by physicians contrary to the recommended evidence-based guidelines has 
potential risks such as increased incidence of  false positives, unnecessary investigations, 
radiation exposure, psychological stress and increased cost without any benefit.9  
It is important to see if the factors affecting decision making for other cancers where 
guidelines are conflicting or the evidence is unclear also apply to the case of lung cancer 
screening. 
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After many years of research, there is no evidence proving the efficacy of CXR as a 
screening test for lung cancer.6 The Memorial-Sloan Kettering11, the Johns Hopkins12 and 
the Mayo Lung Project13 trials evaluated CXR as a stand alone screening test or with 
sputum cytology to screen for lung cancer. Follow-up did not show a difference in lung 
cancer incidence or mortality.11-15 
Prevailing national guidelines for lung cancer screening (at the time of the present study) 
differed in their advice about the use of CXR. The Canadian Task Force on Preventive 
Health Care (CTFPHC) guidelines8 recommended against screening for lung cancer using 
CXR and concluded there was insufficient evidence to screen with low-dose computed 
tomography (LDCT). The USPSTF stated “the evidence is insufficient to recommend for 
or against screening asymptomatic persons for lung cancer with either low-dose 
computerized tomography (LDCT), chest x-ray (CXR), sputum cytology, or a 
combination of these tests.”7, p738  
Nevertheless, in discussions with physician colleagues and departments of radiology, it is 
common to find CXR requisitions for asymptomatic patients for annual or periodic 
exams, which can be assumed to be for screening purposes. To date, there are no formal 
data collected to see whether these tests are being ordered for screening purposes in 
Canada. There is limited research regarding factors that may influence physician 
screening behaviour on lung cancer screening specifically.9  There have been studies on 
physician behaviour on breast, prostate and colorectal cancer.1 
Guidelines from various Canadian sources differ in their recommendations for lung 
cancer screening. The Saskatchewan Health Services Utilization and Research 
Commission16 and British Columbia Council17 recommended against use of CXR. 
However the Manitoba Consensus Group18 recommended CXR for screening differing 
from the prevailing guidelines for lung cancer screening. 
Lung cancer risk among heavy smokers may be as high as 30% 19 compared to non-
smokers. Other risk factors include positive family history of lung cancer20,21 and 
a history of chronic obstructive pulmonary disease (COPD).22  
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Studies reveal LDCT as a promising screening method for lung cancer detection as part 
of periodic health examinations. This could be offered to patients who are identified at 
high risk for lung cancer.23 However, the radiation exposure may be harmful.24 
The literature does not support lung cancer screening with CXR or with sputum 
cytological examination. Risk of inducing anxiety in false positive cases will cause 
unnecessary further testing and radiation. Further research is needed for identifying an 
appropriate approach to screening in clinic practice.25  
Table 1 and 2 summarize the variation in national recommendations for lung cancer 
screening at the time of this study. 
Table  1-1 National Lung Cancer Screening Guidelines 
Screening 
Test 
CTFPHE USPSTF Australia NHS England 
CXR Recommend Against Insufficient Evidence Recommend Against No Recommendation 
CT Scan Insufficient Evidence Insufficient Evidence Recommend Against No Recommendation 
Sputum 
Cytology 
No Recommendation Insufficient Evidence Recommend Against No Recommendation 
 














CXR Recommend Against Recommend Against Recommend Against Recommend 
CT Scan Insufficient Evidence No Recommendation Recommend Against Recommend 
Sputum 
Cytology 
No Recommendation Recommend Against Recommend Against Recommend Against 
Despite the fact that, with one exception (Manitoba), current recommendations are 
against the use of CXR as a screening test for lung cancer, some FPs do screen their 
patients.18 These significant variations in recommendations and practice behaviour 
identifies a gap and indicates that further research is needed to improve  evidence based 
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guidelines that are implementable and will improve preventive care in family 
practice.18,26 
1.2.3 Issues regarding Screening 
The literature suggests that a number of factors are involved in decision-making around 
screening in general:10,27-29  
Physician Perspective: 
• Physicians are a resource to their patients. Physicians prefer to screen, as they like 
to prevent life-threatening illness for their patients.  
• Physicians want to be rated as responsible physicians by their communities 
• It is important  to build patient-physician relationship 
• Physicians may want to protect against litigation if it will come from not offering 
screening tests and by following available best practice guidelines that could 
prevent their patients from illness like cancer 
Patient Perspective: 
• Patients generally expect their physicians to diagnose illnesses 
• Patients expect their physician to diagnose cancers early by ordering lab tests and 
radiological diagnostic tests for their periodic health exams 
• Patients also appreciate and sometimes expect their physicians to educate them 
regarding preventative strategies for cancers 
Issues regarding Guidelines 
• Several guidelines are available as practice resources  
• Some are conflicting and are unclear 
• Some are clear, however may conflict with physicians practice experience and 
don’t take into account the patient’s perspectives. 
Need for Screening 
• Saves healthcare dollars by detecting disease early 
• Savings in cost of treatment through earlier diagnosis 
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• Savings in lives saved 
• Savings in ailments and disabilities in relatives and significant others 
1.2.4 Physicians’ Attitudes about Screening In General 
The literature27 indicates that physicians perform screening tests more often than 
recommended or sometimes do not follow current practice recommendations. The 
CTFPHC and USPSTF screening guidelines are considered the standard for prevention. 
Even when these screening guidelines are thought to be followed, deviation occurs. The 
following reasons were identified:27 
• Lack of knowledge of current guidelines. 
• Patient’s expectation or demand as seen in the case of mammography. 
• High volume of patients who are at risk for developing cancer. 
• The physician has concerns regarding the sensitivity and effectiveness of 
screening methods. 
• The guidelines that make recommendations also comment on the evidence being 
insufficient, which may decrease physician confidence in the recommendation. 
• There is an economic benefit for the physician from ordering frequent tests for 
screening. 
An American study used online surveys to determine attitudes of physicians regarding 
cholesterol and heart disease. It found that most of the physicians surveyed, (who were 
from pre-existing independent panels) felt they followed the National Cholesterol 
Education Program Adult Treatment Panel III guidelines, but felt that other physicians 
did not follow them. The attitudes of physician and consumers were similar in 
recognition of the significant health link between cholesterol and coronary artery disease, 
but differ in why patients do not take prescription medications.30 
With a lack of knowledge about what actually influences physicians’ attitudes toward 
screening, an American study examined the influence of actual or perceived state policy 
on pediatricians’ attitudes toward screening. It found variations in support for the 
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screening guidelines considered in the study. It showed that pediatricians who believed 
the State had a policy of screening were more supportive of screening.31 
In the absence of literature on the topic, an American study was undertaken to determine 
FPs’ knowledge about sexually transmitted infections (STIs) management. The study 
demonstrated that physicians with good knowledge of STI guidelines were more likely to 
do routine screening of women at high risk for contracting Chlamydia infections. It was 
also identified that lack of knowledge was a barrier to following recommended screening 
for STIs. Educational and dissemination interventions were recommended.32 
A U.S. study found there was substantial variation across medical offices in Chlamydia 
screening for at risk women. Further research was suggested to understand predictors of 
better office performance with the goal of more effective interventions promoting 
screening.33 
FPs’ screening practices vary depending on the medical condition being screened and 
FPs’ beliefs and practices. A study on FPs’ hepatitis C management found little use of a 
standardized history-taking form for disease-specific screening, something shown to be 
necessary, to screen for other medical conditions.34 
In summary, the literature shows physicians’ screening practices vary and differ from 
guideline recommendations. Physician attitudes about screening in general are influenced 
by knowledge (or lack thereof), differing recommendations, perceptions of state policy 
and sometimes personal preference. 
1.2.5 Physician attitude towards Cancer Screening 
An Alberta, Canada study explored the attitudes of specialists for colorectal cancer 
(CRC) screening practices, the year after a national CRC screening guideline was 
released. The results showed specialty-based variations in their practices and significant 
overall common practice and personal beliefs/attitudes for self-treatment which went 
against the CTFPHE guidelines, in which colonoscopy was not recommended.35 This 
might be because specialists see a pre-screened population of patients and screening 
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guidelines that might be appropriate for primary care may not necessarily be appropriate 
for secondary care. 
A U.S. survey study examined physician attitudes to prostate cancer screening at a health 
care facility for Veteran Affairs. The survey questionnaire asked what risk factors 
influence FP’s' decision to screen patients for prostate cancer.  The study concluded FPs 
recognized elevated risk for African-Americans and  a family history of prostate cancer 
but frequently screened elderly or patients with a limited  life expectancy, which was not 
within guidelines.36 
An Italian survey study explored CRC screening knowledge, attitudes and practices of all 
general practitioners (GPs) in Lazio, Italy. The response rate was 59%. Ninety four 
percent believed CRC was preventable. Knowledge was higher in physicians using 
screening guidelines. Twenty-five percent recommended screening tests, 22% did not 
recommend and 47% over-recommended. The study investigators felt the low response 
rate was indicative of GP’s lack of interest in screening.37 
In summary, lack of interest in screening, logistical barriers and a lack of awareness of 
cancer information and research services were identified as factors relating to low cancer 
screening rates by FPs.  
1.2.6 Physicians’ attitudes and practices regarding Lung Cancer 
Screening 
Physicians’ attitudes and beliefs towards screening for lung cancer have been recently 
studied in a  U.S. prospective descriptive survey9, mailed to FPs, internists and 
pulmonologists. The response rate was 303/3000 (10%) with 71% FPs and 29% 
pulmonologists. Physicians were identified as high screeners, low screeners or no 
screeners. Physicians were also asked to describe factors that influence ordering of 
screening tests. 
The study showed the relative importance of factors (highest to lowest) to physicians 
when assessing a screening program: 
1. If there was proven clinical efficacy 
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2. If the test was recommended by USPSTF 
3. If randomized control trials  improved mortality rate 
4. If the test was sensitive 
5. If the test was cost effective 
Despite the low response rate, the researchers concluded that a substantial number of 
physicians screen for lung cancer using CXR (25%)  even though guidelines are against 
its use as a screening test. Pulmonologists screen more than family practitioners do and 
the number of years in clinical practice was directly related to screening behaviour. 
“Screening outside accepted guidelines has potential risks including false-positive 
results, unnecessary invasive procedures, radiation exposure, psychological stress, and 
increased costs to the health care system.”9, Clinical Implications 
A large scale U.S. national study38,39 of FPs showed lung cancer screening tests such as 
CXR were commonly ordered even though unsupported by guidelines. Other research 
shows FPs screen for lung cancer,26,40,41 including one study42 which found 10-90 % of 
PCPs reporting they do so.  
A U.S. qualitative study of physicians’ lung cancer screening practices used telephone-
conducted focus groups.43 Participants consisted of 17 internists and 11 FPs. That study 
identified seven factors influencing physicians’ decision to screen for lung cancer: five 
physician factors and two patient factors. Physician factors were perception of the 
effectiveness of screening; guideline recommendations; practice experience; perception 
of patient’s risk factors for lung cancer and fear of litigation. Patient factors were patient 
request for screening and ability to pay for the screening procedure. 
1.2.7 Physicians’ attitudes towards use of Guidelines 
Family physicians play a vital role in cancer screening. The attitudes of family physicians 
towards guidelines have been explored. A study by the Ottawa Health Research 
Institute44 explored the family physician’s views on cancer screening guidelines. It was 
found that guidelines sometimes add controversy and barriers to the decision-making 
process. FPs expect guideline developers to provide them with the resources to help in 
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their decision-making process by providing clear guidelines in an easy-to-use format on 
topics identified by them as relevant to their practice. 
Since FPs involve their patients in care, including patient involvement in decision-
making, FPs expect guidelines/decision-making tools be made available to them in an 
interactive format which they can use with their patients in the office setting.44  
A German study of general practitioners and internists studied knowledge of secondary 
prevention of coronary heart disease. It also studied their perception of guidelines and 
how that perception influenced their treatment practices. Results showed that increased 
knowledge of guidelines was directly related to improved management of risk factors for 
heart disease. However, many physicians who were aware of guidelines chose to treat in 
a way that differed from guidelines.45 
In a study that assessed knowledge and beliefs of American physicians and how they 
influenced their practices in managing colorectal cancer screening, it was found that most 
providers recommended screening-guidelines, but patient refusal was common. Usual 
practice often did not follow evidence-based guidelines.46  
A systematic review of studies on clinician’s attitudes to clinical practice guidelines was 
conducted covering years 1990-2000.47 Clinicians agreed guidelines were helpful and 
useful as educational tools and believed they tend to improve quality of care. However, 
they also found guidelines to be impractical; some felt they were very rigid and 
inapplicable to individual patient situations. They also felt guidelines reduced physician 
autonomy and were oversimplified. Most expressed the view that guidelines are intended 
to cut costs in healthcare. Some also feared that use of guidelines may increase 
litigation.47  
1.2.8 Influence of Guidelines on Physician Behaviour 
Studies have been conducted to understand the influence of guidelines on physician 
behaviours and practices. For example, a US survey study was conducted to explore FPs’ 
attitudes and practices regarding Periodic Health Exam. The study revealed that FPs do 
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not follow recommendations to use more selective health care approaches for 
prevention.48 
Physician factors may affect screening guideline compliance. Compliance with American 
Cancer Society CRC screening guidelines was associated with physician’s perception of 
risk for CRC in one study.49 
A U.S. study assessed the knowledge, perception, and behaviour of family physicians 
regarding management of dyslipidemia. The study found variability in all three among 
family physicians and also an overall variability in adherence to guidelines.50 
All FPs in Newfoundland and Labrador, Canada were surveyed on their prostrate cancer 
screening practices, attitudes and continuing medical education (CME) preferences. The 
study found physicians were supportive of screening, but their beliefs and practice varied 
- one half questioned the reliability and evidence to support digital rectal exam (DRE)  
for screening, and one third questioned both DRE and PSA testing, motivating a need for 
CME to address identified issues with prostate screening.51 
In summary, physicians’ practices vary from one another and may differ from guidelines. 
Physicians have a wide variation in knowledge, beliefs and practice patterns. In general, 
physicians were supportive of screening, however, their beliefs and practices varied from 
guideline recommendations. They also questioned the evidence supporting the guidelines.  
1.2.9 Current Evidence about Guidelines for Lung Cancer 
Screening 
At the time the survey was completed (2012), the prevailing guideline from the Canadian 
Task Force on Preventive Health Care (CTFPHC)8 concluded that “there is fair evidence 
to recommend against screening asymptomatic people for lung cancer using chest 
radiographic examination (D recommendation).”8, p1  
The CTFPHC concluded “there is insufficient evidence (in quantity and/or quality) to 
make a recommendation as to whether spiral CT scanning should be used for screening 
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asymptomatic people for lung cancer. However, other factors may influence decision-
making. (I recommendation)”8, p1 
At the time the survey was completed, the prevailing guideline from the U.S. 
Preventative Services Task Force (USPSTF) was the 2004 recommendation for lung 
cancer screening, stating that “the evidence is insufficient to recommend for or against 
screening asymptomatic persons for lung cancer with either low-dose computerized 
tomography (LDCT), chest x-ray (CXR), sputum cytology, or a combination of these 
tests.This is a grade I recommendation.”7, p738  
The current Cancer Council of Australia health guideline states “No forms of population 
screening for lung cancer, including regular chest radiography, with or without sputum 
cytology even in high-risk groups, have been shown to improve outcomes and screening 
is not recommended. In view of the limited information available on outcome, helical CT 
screening for lung cancer is not recommended except in the context of a well- designed 
clinical trial.”52, pxiv 
In the 2014 update of their 2004 recommendation, the USPSTF4 recommended certain 
people at high risk for lung cancer be screened with low dose CT scan annually. The 
high-risk people were defined as current smokers or smokers who have quit within the 
last 15 years, in adults aged 55-80 who have a 30 pack-year smoking history. A pack year 
was defined as smoking an average of one pack of cigarettes per day for one year. 
Screening should be discontinued once a person has not smoked for 15 years or 
developed a health problem that substantially limits life expectancy or the ability or 
willingness to have curative treatment for lung cancer. This guideline was graded as 
category B meaning “there is high certainty that the net benefit is moderate or there is 
moderate certainty that the net benefit is moderate to substantia.”4, Appendix, Table 1 
1.2.10 Post Survey – Recent Literature Summary 
Subsequent to survey instrument development and data collection, recent related research 
was published. A Scopus search was conducted to bring the literature review up to date. 
It found 25 articles that cited Haggerty2, the most recent publication in the series of 
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research that this thesis extends2,10,28,53. Three have relevance to physician decision 
making. One54 investigated which factors influenced physician decision to order PSA 
screening tests. Although factors included some of those studied in this thesis research, 
others were dissimilar, and the survey methods and analysis were dissimilar and unsuited 
for adaptation or comparison. Another study55 explored which patient and physician 
factors influenced cervical cancer screening over and under use. This was not a survey 
study, but instead collected actual ordering data. The third study56 involved a survey 
instrument completed by both physician and patient regarding attitudes to shared care and 
influence on specialist referrals. The instrument and methods were dissimilar to that used 
in the current study.  
Updates to guidelines for lung cancer screening were also made, with modified 
recommendations. The changes have already been discussed in section  1.2.9 above. 
1.3 Identification of Research Opportunity 
Lung cancer is a prevalent cancer and accounts for significant mortality. There are not 
many helpful strategies available for dealing with lung cancer prevention other than 
counselling smoking cessation and detection at an earlier stage. There are not many 
treatments that are very useful for treating lung cancer. FPs have regular contact with the 
patient population at risk for disease and the physician group most likely to screen for 
diseases. As their patient population includes smokers, FPs are concerned about them and 
face the challenge of what can they do which would be helpful in detecting lung cancer at 
early stages.  
In summary, lung cancer is a prevalent disease and those at higher risk, such as those who 
smoke are frequently attended in family physicians’ offices where screening may be 
taking place. 
The literature has been reviewed in terms of the effectiveness of lung cancer screening 
tests. Recommendations are conflicting regarding use of screening tests. At best, there is 
insufficient evidence to recommend routine screening with CXRs. Some guideline panels 
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have stated there is enough evidence to say that CXR is not effective and have 
recommended against routine screening while others do recommend it.  
Regardless, the literature confirms that some FPs do screen with CXRs.  There appears to 
be a dissonance between what people reviewing the evidence suggest and how certain 
FPs are behaving. The literature shows a gap between recommendations and behaviour in 
practice and that there is a need to examine some of the various reasons for this gap.  
There is also literature that has looked at cancer screening generally and in the context of 
uncertainty.38,39,43,57 
Therefore, to try to understand this gap, it is important to understand how often FPs 
report they are screening for lung cancer, what screening tests they order and the factors 
that influence them to behave in a way that is different than some experts have suggested 
the evidence would indicate or direct.  
Understanding this is important for several reasons. In economic terms, if resources are 
being used that are not effective, then they are not available for other purposes. It will 
provide insights in terms of helping FPs understand guidelines better and aid in 
adherence. It will help guideline developers to understand how they might improve 
adherence to recommendations by understanding how intended users make decisions 
around screening and the many factors that influence their decision-making. 
1.4 Research Questions 
The following research questions were explored:  
1. What do family physicians practicing in urban and rural Saskatchewan report they 
do regarding their lung cancer screening practices?  
2. Which lung cancer screening test(s) do family physicians practicing in urban and 
rural Saskatchewan report they use?  
3. Which factors influence the decision-making of family physicians practicing in 
urban and rural Saskatchewan when presented with hypothetical clinical 
scenarios? 
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1.5 Objectives 
The study objectives were: 
1. To estimate the frequency with which FPs order lung cancer screening tests. Data 
were used to identify two groups of FPs: 
a) Screeners, defined as those who report they order lung cancer screening tests for 
asymptomatic ever smokers; 
b) Non-Screeners, defined as those who report they do not order lung cancer 
screening tests for patients who are asymptomatic ever-smokers. 
2. To determine how frequently CXR was ordered as a screening test. Since the 
CTFPHE recommendations are clearly against the use of CXR as a screening test, the 
survey specifically questioned about the use of CXR. 
3. To determine the factors that influence lung cancer screening decision-making. 
This research explored FPs’ reported lung cancer screening behavior based on factors 
identified in the literature that influenced screening decision-making for other cancers 
such as breast, colon and prostate. The literature revealed no research to-date that studied 
the influence of any of these factors on lung cancer screening decision-making in Canada. 
This study incorporates these factors into a proposed model shown in Figure  1-1. 
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Figure  1-1 Conceptual FP Lung Cancer Screening Decision Making Model  
This illustrates the author’s initial concept of the factors involved in a physician’s lung 
cancer screening decision-making based on the literature. It illustrates patient, physician 
and non-medical factors that are identified in the literature as factors influencing cancer-
screening decision-making for breast, colon and prostate cancers.2,10 This study used 
clinic scenarios in the survey to explore whether these factors also influenced lung cancer 
decision-making behaviour. 
Patient Factors:† 
a) Patient’s expectation to be screened 
b) Anxiety about having lung cancer 
c) Positive family history of lung cancer 
d) Influence of patient-physician relationship 
Physician Factors: ‡ 
a) Perception of guidelines 
b) Clinical practice experience 
c) Any other factor that influences decision making 
d) Physician demographics 
i) Gender  
ii) Age 
iii) CCFP certification 
iv) CFPC membership 
v) Years of family practice 
vi) Type of practice 
vii) Location of practice 
viii) Family practice hours 
ix) Teaching responsibilities 
Non-Medical Factors:§ 
a) Influence of practice of colleagues 
b) Influence of specialists 
c) Time constraints 
d) Accessibility and cost of test and cost 
Order Screening test(s): 
□ CXR? 
□ CT Chest? 
□ Sputum Cytology? 
Where Factors are queried in Survey 
† Patient factors are studied in Section II and Section III, Clinical Vignettes. 
§ Non-medical factors are studied in Section II.  
‡ Physician factors are studied in Sections I, II and IV. 





The CTFPHC and USPSTF guidelines for lung cancer screening at the time of the study 
differed slightly but none recommended screening with CXR. However, there is 
uncertainty about family physicians’ (FPs) lung cancer screening practices in clinical 
encounters - whether FPs screen for lung cancer, what screening test do they order and 
how often do they screen despite guideline recommendations.  
This study identified whether Saskatchewan FPs screen for lung cancer and what factors 
influenced them to do so. It consisted of a cross-sectional survey and measured FPs’ 
responses to self-reported screening behaviour questions and to hypothetical clinical 
screening scenarios. These two outcomes were analyzed separately. 
2.2 Design 
This study consisted of a cross-sectional survey with two components: 
1. Questions designed to measure physicians’ self-reported behaviour and  
2. Hypothetical clinical scenarios designed to determine physician’s intended 
behaviour in different situations.  The data collected from these two components 
were analyzed separately.  
2.3 Sample 
The study respondents were FPs practicing in rural, regional and urban areas of 
Saskatchewan.  
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2.3.1 Inclusion Criteria 
Only physicians who worked more than fifteen hours per week in family practice (i.e. 
deemed to be full-time) were included. This maintains consistency with the classification 
used in comparable research by Tudiver et al.2 
2.3.2 Exclusion Criteria 
Specialist physicians practicing internal medicine, surgery, pulmonology, neurology, 
pathology, radiology and any other specialities were excluded from the study. 
2.4 Survey Questionnaire Development 
The method of data collection used was survey via a self-administered paper 
questionnaire. A mail survey package was developed for distribution, including a letter of 
information, a survey questionnaire and a stamped return envelope (Appendices A & B). 
This study’s objectives were consistent with Tudiver et al. except that they studied breast, 
colon and prostate screening behaviours of FPs whereas this study specifically explored 
lung cancer screening behaviour of FPs.  
Tudiver’s survey instrument (Appendix C) was adapted because of the benefit of 
employing a previously validated methodology. The survey was modified to study lung 
cancer screening behaviour. Appendix D describes the systematic and rigorous 
adaptations made to the Tudiver survey. 
2.5 Variables 
2.5.1 Outcomes 
Two outcomes were measured: 
1. Based on their self-reported screening behaviours, physicians were dichotomized 
into Screeners and Non-Screeners. We defined Screeners as physicians who 
  20 
 
ordered screening tests for lung cancer if they reported they routinely ordered 
screening tests for asymptomatic patients who are ever-smokers (Section II, 
question 2a). Similarly, physicians who reported they did not order lung cancer 
screening tests for asymptomatic ever-smokers were defined as Non-Screeners 
(Section II, question 2a).  
2. Based on their responses to clinical scenarios (Section III), FPs’ intended decision 
to order a lung cancer screening test with dichotomous variables (yes or no). This 
was based on six hypothetical scenarios: 
a) Scenario 1 was considered uncomplicated. 
b) Scenarios 2 to 5 each contained a complicating dynamic: expectation, anxiety, 
family history, poor patient-physician relationship respectively. 
c) Scenario 6 contained all four complicating dynamics. 
d) For each scenario, respondents indicated whether they would order any of 
three possible screening tests: CXR, CT chest and sputum cytology 
2.5.2 Predictor Variables 
Several characteristics of the physician and non-medical factors have been shown to 
influence physicians’ screening behaviour.10 Therefore the self-reported Screeners and 
Non Screeners were compared by the following independent variables: 
1. Physician Factors: 
a) Physician characteristics (as outlined below) (Section IV): 
i. Gender (question 1) 
ii. Age group (question 2) 
iii. Certification by The College of Family Physicians of Canada (CCFP) 
(question 3) 
iv. Professional membership in the College of Family Physicians of Canada 
(question 4) 
v. Number of years of family practice (question 5) 
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vi. Type of practice: solo, group (question 6) 
vii. Location of practice: urban vs. non-urban-(regional were coded as non-
urban (question 7) 
viii. Number of practice hours per week (question 8) 
ix. Teaching responsibilities (question 9) 
b) Attitudes toward screening (Section II, question 3-13) 
c) Perception of guidelines (Section I, questions 1-3) 
d) Screening behaviour (Section II, questions 1-2) 
2. Non-Medical Factors (Section II, questions 14c-h): 
a) Influence of practice colleagues 
b) Influence of specialist colleagues 
c) Cost of the test 
d) Accessibility of test 
e) Ease of administration 
f) Time constraints 
Several patient factors have been identified as the most important determinants of cancer 
screening decision-making for breast cancer, colorectal cancer and prostate cancer.10 This 
study measured if they also influenced the physicians’ decision to screen for lung cancer 
in hypothetical clinical scenarios. These factors were: 
1. Patient Factors, self-reported behaviour (Section II, questions 14a-b): 
a) Patient’s expectations to undergo screening 
b) Anxiety about having lung cancer 
2. Patient Factors, measured behaviour (Section III): 
a) Patient’s expectations to undergo screening (Scenario 2) 
b) Anxiety about having lung cancer (Scenario 3) 
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c) Positive family history of lung cancer (Scenario 4) 
d) Quality of the patient-physician relationship (Scenario 5) 
2.6 Data Collection 
A distribution list was generated from the College of Physicians and Surgeons of 
Saskatchewan registry and the Regional Health Authority administration offices. A 
stratified sample of FPs who met the inclusion criteria were recruited by mailing them a 
complete survey package. 
To increase the external validity of the study, a high rate of return was desired. The 
survey was distributed and administered using methods known to enhance physician 
participation. A revised, step-wise Dillman Method58 was used to encourage response: 
1. Initial mailing 
2. Follow up reminder postcard 
3. Second full mailing 
4. Phone call reminder  
2.7 Data Entry 
The Primary Investigator (PI) (author) set up the SPSS data dictionary to correctly code 
the item types and values needed. Raw data from each uniquely numbered survey 
questionnaire booklet was entered to produce the SPSS database in preparation for 
statistical analysis. Some respondents returned partially completed surveys or provided 
unexpected multiple responses; all were directly coded as provided. Details of how such 
were accommodated are provided in Chapter 3 Results. 
Quality was managed by conducting one hundred percent checking. This was jointly 
performed post data entry by the PI and an assistant, who compared the coded data with 
each survey booklet and reconciled any discrepancies.  
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2.8 Data Analysis 
Appropriate analysis of the data collected from the survey was done using SPSS 
Version 19.  
Analysis – Outcome #1 
Bivariate analysis examined whether there were any associations between Screeners and 
Non-Screeners on physician characteristics, attitudes toward screening, perception of 
guidelines and screening behaviour: 
Mann-Whitney-U tests were conducted for continuous independent variables and Chi-
Square was used for categorical variables.  
Analysis – Outcome #2  
Analyses were conducted with the outcome of whether to order one of three possible 
screening tests in each of the five complicated scenarios. Therefore, 15 comparisons were 
made (three possible tests by five possible scenarios); each analysis compared decisions 
made in the uncomplicated scenario against the decision made by the same physician in 
one of the five complicated scenarios. Due to the repeated nature of the study in that the 
same participants were asked to provide their screening responses under different 
conditions, McNemar’s Chi square test was used to assess if the proportion that would 
screen differed between the each of complicating dynamics (Scenarios 2 to 6) and the 
uncomplicated scenario (Scenario 1).  Because differences in proportions will be the 
result of participants changing their screening practices under the different conditions, 
and that these changes can be in either direction (i.e. from “not screen” in the 
uncomplicated scenario changing to “screen” in complicated or “screen” in 
uncomplicated changing to “not screen” in complicated), it is the net difference in this 
change that is statistically important. 
Additionally, the influence of recommendation perception on screening behaviour was 
assessed. Analyses were conducted comparing the proportion of physicians who would 
screen using each test in each of the scenarios against their perceptions of the guidelines 
  24 
 
being recommended or not recommended respectively. Due to the repeated nature of the 
study, recognizing that the same participants were assessed concerning their practice 
within multiple scenarios, the association between the perception that the test is 
recommended and whether or not it was performed was evaluated for each scenario 
separately. To account for multiple testing, Bonferroni correction was applied to the 
significance level, with 0.05 divided by 6 scenarios to produce a new alpha of 0.008.  
Only statistical test results with p-values below this level were considered statistically 
significant. 
2.9 Reliability and Validity 
To ensure validity and to ensure appropriateness of the reading level, the survey was 
piloted on three FPs. This was followed by an interview to improve clarity and 
comprehensiveness of the questionnaire.  
This study also contains a section, consisting of clinical case scenarios where testing is 
done in the context of a controlled environment, one where independent variables are 
manipulated to examine decision-making behaviour. In this section, the strength of the 
internal validity is not felt to be at the expense of external validity; the clinical scenarios 
presented are intended to model a real-world clinical encounter. 
References on questionnaire design and quality assessment were consulted during 
questionnaire development.59-68 
To increase the external validity of the study, a high rate of return was desired. This was 
promoted in this study by using best practices identified in the literature including 
administration of the survey using the step-wise revised Dillman Method, discussed in 
Section   2.6 above. 
2.10 Ethics Approval 
Ethics approval was obtained from the Research Ethics Board of the University of 
Western Ontario (Appendix F). 





This study consisted of a cross-sectional survey of family physicians (FPs) practicing in 
Saskatchewan.  Of the 250 FPs contacted, 49 responses were deemed acceptable, after 
adjusting for surveys which were incomplete on key questions, yielding a final response 
rate of 20%. The demographics of the final study participants are presented in Table  3-1 
(Questionnaire Section IV); available provincial and national data are also listed for 
comparison. In spite of the small sample size and the low response rate, the 
characteristics of the study sample are similar to those for Saskatchewan and Canadian 
FPs, offering some support for generalizability of the findings. However, the sample has 
a higher proportion of female and rural FPs, compared to the provincial or national 
populations. 
Based on their reported practice behaviour (Section II, question 2a), FPs were divided 
into two groups, Screeners and Non-Screeners, defined as: 
1. Screeners - those who report they order lung cancer screening tests for 
asymptomatic ever-smoking patients; 
2. Non-Screeners - those who report they do not order lung cancer screening tests 
for asymptomatic ever-smoking patients. 
Out of 49 FPs, 34 (69%) were classified as Screeners and 15 (31%) as Non-Screeners. Of 
those who screened, CXR was ordered by up to 73% of FPs making it the most 
commonly ordered screening test contrary to prevailing guidelines. 
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Table  3-1 Physician Characteristics 
Physician Factors    
 All participants 




(N = 1089)*† 
Total Canadian 
FP Population 
  (N = 34 810)*† 
Sex, n (%)    
Male 25 (52%) (69%) (59.6%) 
Female 23 (48%) (31%) (40.4%) 
    
Age, n (%)    
<50 years 32 (67%) † † 
≥50 years 16 (33%) † † 
    
CCFP certification, n (%)    
Yes 24 (50%) (51.9%) (54.6%) 
No 24 (50%) (48.1%) (45.4%) 
    
CFPC membership, n (%)    
Yes 44 (92%) † † 
No 4 (8%) † † 
    
Group practice, n (%)    
Yes 38 (81%) (82.2%) (78%) 
No 9 (19%) (17.8%) (22%) 
    
Teaching affiliation, n (%)    
Yes 21 (44%) † † 
No 27 (56%) † † 
    
Practice location, n (%)    
Urban 25 (52%) (55.3%) (63%) 
Rural/regional 23 (48%) (44.7%) (37%) 
    
Practice hours/week,    
Mean (SD) †† 30.8 (13.8) † † 
Median (IQR) †† 35 (24, 40) † † 
    
Years in practice    
Mean (SD) †† 13.9 (12.2) † † 
Median (IQR) †† 30.8 (13.8) † † 
*National Physician Survey 2010, The College of Family Physicians of Canada, 
Canadian Medical Association and Royal College of Physicians and Surgeons of Canada 
† Comparable datum not available from National Physician Survey 2010 because it was 
either not collected, definitions differ from current study or not reported 
**Participants within column may not sum to N due to missing values 
††SD stands for standard deviation, IQR for Interquartile range 
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3.2 Physician Factors and Screening Behaviour 
Table  3-2 presents the results for physician factors and compares Screeners and Non-
Screeners (Questionnaire Section IV). A statistically significant difference was found 
where Screeners worked more hours per week than Non-Screeners. Differences were 
marginally significant for practice location; Screeners were more likely to be from rural 
practices (56%) versus Non-Screeners (29%). There were no statistically significant 
differences for the remaining variables. 
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Table  3-2 Physician Factors and Screening Behaviour 
Physician Factors  Screening practices, n (%)*  
 All 
participants 
(N = 49)‡ 
Screeners 
(n = 34) 
Non-
Screeners 
(n = 15‡) 
p-
value§ 
Sex, n (%)     
Male 25 (52) 18 (53) 7 (50) 0.85 
Female 23 (48) 16 (47) 7 (50)  
     
Age, n (%)     
<50 years 32 (67) 25 (74) 7 (50)  
≥50 years 16 (33) 9 (27) 7 (50) 0.18** 
     
CCFP certification, n (%)     
Yes 24 (50) 16 (47) 8 (57) 0.53 
No 24 (50) 18 (53) 6 (43)  
     
CFPC membership, n (%)     
Yes 44 (92) 30 (88) 14 (100) 0.31** 
No 4 (8) 4 (12) 0 (0)  
     
Group practice, n (%)     
Yes 38 (81) 26 (77) 12 (92) 0.41** 
No 9 (19) 8 (24) 1 (8)  
     
Teaching affiliation, n (%)     
Yes 21 (44) 13 (38) 8 (57) 0.23 
No 27 (56) 21 (62) 6 (43)  
     
Practice location, n (%)     
Urban 25 (52) 15 (44) 10 (71) 0.09 
Rural/regional 23 (48) 19 (56) 4 (29)  
     
Number of practice 
hours/week, 
    
Mean (SD) 30.8 (13.8) 34.9 (10.6) 21.0 (16.1)  
Median (IQR) 35 (24, 40) 36 (27.3, 40) 16.5 (8.3, 
36.3) 
0.006 
     
Number of years in practice     
Mean (SD) 13.9 (12.2) 13.5 (11.6) 14.8 (14.1)  
Median (IQR) 30.8 (13,8) 10.5 (3.8, 20) 7 (3.3, 30.3) 0.95 
*Denominator is the number of participants responding to the question 
‡
 Totals within columns do not sum to n due to missing values. 
§p-values comparing Screeners and Non-Screeners’ screening practices for 
categorical variables assessed by Chi square test with **Fisher’s exact test where 
indicated.  Medians for continuous variables compared by Mann-Whitney-U testing.   
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3.3 Physician Attitudes & Practices by Screening Group 
Table  3-3 compares FPs’ lung cancer screening attitudes and practices by screening 
group (Questionnaire Section II, questions 3-13). Participants’ agreement with statements 
listed in the table, was dichotomized as yes or no responses. The following discussion of 
important findings makes brief mention of the corresponding statements; please refer to 
the table for the full statement text.  
A significantly larger proportion of Screeners (85%) than Non-Screeners (50%) agreed 
with the statement that missing a case of lung cancer would result in increased screening 
for some time afterwards.   
Similarly, a significantly larger proportion of Screeners (67%) than Non-Screeners (21%) 
agreed with the statement that they would routinely screen if there was a positive family 
history of lung cancer. 
A significantly larger proportion of Screeners (88%) than Non-Screeners (57%) agreed 
with the statement that they would routinely screen if there was occupational exposure 
such as asbestos, silica and chemicals. 
A significantly larger proportion of Screeners (79%) than Non-Screeners (29%) agreed 
with the statement that they would routinely screen if there were co-morbid conditions 
such as COPD 
A significant minority of Screeners (13%) and a majority of Non-Screeners (79%) agreed 
with the statement that they would not recommend CXR for screening because they 
thought there was potential to cause more harm than good.  
Medico-legal considerations had no impact on screening behaviour among FPs in either 
group. 
Both Screeners and Non-Screeners were equally likely to apply lung cancer guidelines to 
each individual patient’s needs. 
   
   
Table  3-3 Physicians’ agreement with statements on attitudes and practices by screening group 
Statement Agreement 
 Screeners 
n = 34 
 Non-Screeners 











The guidelines for lung cancer screening are just 
guidelines.   
27 (82) 
 
6 (18)  14 (100) 
 
0 (0) 0.16 




8 (24)  11 (79) 
 
3 (21) 1.0 
I tend to follow lung cancer screening guidelines when they 
are published by an organization that I trust. 
31 (94) 
 
2 (6)  12 (86) 
 
2 (14) 0.57 
If I missed a case of lung cancer I would tend to screen 




5 (15)  7 (50) 
 
7 (50) 0.03 
I will routinely recommend a lung cancer screening test 




26 (79)  2 (15) 
 
11 (85) 1.0 
I will routinely recommend a lung cancer screening test for 
patients if there is a positive family history of lung cancer 
22 (67) 
 
11 (33)  3 (21) 
 
11 (79) 0.009 
I will routinely recommend a lung cancer screening test for 
asymptomatic patients when there is a history of 




4 (12)  8 (57) 
 
6 (43) 0.046 
30 
   
   
Statement Agreement 
 Screeners 
n = 34 
 Non-Screeners 
n = 15 
p-value† 
I will routinely recommend a lung cancer screening test 
when patients have co-morbid conditions such as COPD. 
26 (79) 
 
7 (21)  4 (29) 
 
10 (71) 0.002 
I do not recommend CXR for lung cancer screening 




28 (88)  11 (79) 
 
3 (21) <0.0001 
I do not recommend CT Chest for lung cancer screening 
because I think it has the potential to cause more harm 
than good.  
20 (63) 
 
12 (38)  10 (71) 
 
4 (29) 0.74 
*Denominator is the number of participants responding to the question. 
† p-values comparing Screeners and Non-Screeners screening practices for categorical variables assessed by Fisher’s 
exact test due to frequent small expected cell sizes. 
Number of responses to a specific statement within the groups may not sum to group total due to missing values. 
Percentages may sum to more than 100% due to rounding. 
 
31 
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3.4 Physicians’ Perceptions of Lung Cancer Screening 
Guidelines 
Table  3-4 reports FPs’ perceptions of lung cancer screening guidelines (Questionnaire 
Section I). There was a statistically significant difference in that Screeners were more 
likely (52%) than Non-Screeners (7%) to perceive that CXR was recommended for their 
smoking patients. There were no statistically significant differences for the remaining 
variables. Of note, Screeners (69%) and Non-Screeners (46%) found the guidelines for 
lung cancer screening for asymptomatic smokers to be unclear. 
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Table  3-4 Perceptions of Lung Cancer Screening Guidelines 
Guideline Perception 
 by test 







    
CXR     
Recommended, n (%‡) 6 (12) 6 (18) 0 (0) 0.16 
Not recommended§, n (%) 43 (88) 28 (82) 15 (100)  
     
CT scan     
Recommended, n (%) 2 (4) 2 (6) 0 (0) 1.0 
Not recommended, n (%) 47 (96) 32 (94) 15 (100)  
     
Sputum cytology     
Recommended, n (%) 4 (8) 3 (9) 1 (7) 1.0 
Not recommended, n (%) 45 (92) 31 (91) 14 (93)  
     
For ever-smokers 
    
CXR     
Recommended, n (%) 18 (38) 17 (52) 1 (7) 0.003 
Not recommended, n (%) 30 (62) 16 (49) 14 (93)  
     
CT scan     
Recommended, n (%) 7 (15) 6 (18) 1 (7) 0.41 
Not recommended, n (%) 41 (85) 27 (82) 14 (93)  
     
Sputum cytology     
Recommended, n (%) 9 (18) 8 (24) 1 (7) 0.24 
Not recommended, n (%) 40 (82) 26 (77) 14 (93)  
     
Clear guidelines for ever-
smoking patients, n (%)     
Yes, n (%) 17 (38) 10 (31) 7 (54) 0.19 
No, n (%) 28 (62) 22 (69) 6 (46)  
†p-value comparing Screeners and Non-Screeners screening practices assessed by 
Fisher’s exact test due to frequent small expected cell sizes.   
‡Denominator for all percentages is the number of participants responding to the question 
§Not recommended responses to all questions include “recommended against”, 
“insufficient evidence” and “conflicting guidance” 
**Participants within columns may not sum to N or n due to missing values 
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3.5 Choice of Screening Test among Screeners by 
patient’s smoking status 
Table  3-5 reports the choice of screening tests (Questionnaire Section II, questions 1 b 
and 2 b) among Screeners. Since the criterion for Screeners and Non-Screeners was 
based on whether or not FPs screen asymptomatic, ever-smoking patients, FPs in the 
Screener group will all indicate that they screen these patients while Non-Screeners by 
definition will not have screened, and, unsurprisingly, all of them indicated that they 
would not screen never-smokers either. Among Screeners, 16 of the 34 FPs (47%) also 
screened never-smokers. So although Screeners are more likely to indicate at least some 
degree of screening among never-smokers compared to Non-Screeners, the data suggest 
that this tendency is still considerably less than when evaluating ever-smokers (100%). 
Among Screeners, CXR was the most frequently ordered test (97%) for ever smoking 
patients and (94%) for never smoking patients. 
Table  3-5 Choice of Screening Test by Smoking Status among Screeners 
(n=34) 
 Never-smokers 
(Section II Q 1 b) 
 Ever-smokers 
(Section II Q 2 b) 
    
Screening Test    
CXR, n (%)    
Yes 15 (94)  33 (97) 
No 1 (6)  1 (3) 
Would not screen 
 
18*    
CT, n (%)    
Yes 0 (0)  2 (6) 
No 16 (100)  32 (94) 
Would not screen 18*   
Sputum, n (%)    
Yes 5 (31)  8 (24) 
No 11 (69)  26 (77) 
Would not screen 18*   
*Out of 34 Screeners(FPs who will order screening test in ever-smoking patients)  18 did not 
report ordering screening tests in never-smoking patients 
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3.6  Influence of Non-medical Factors on Screening 
Behaviour 
Table  3-6 reports the influence of non-medical factors on screening behaviour 
(Questionnaire Section II, questions 14a-14h). Results were not statistically different for 
the variables but approached marginal significance in their screening behaviour if the test 
was easily accessible or if the test was easy to administer, Screeners more frequently 
order screening tests (77%) than Non-Screeners (50%). 
Table  3-6 Physician agreement that non-medical factors would influence 
test ordering behaviour 
Statement Screeners 
n = 34 
 Non-Screeners 












A patient is anxious about having the 
disease 
29 (85) 5 (15)  9 (69) 4 (31) 0.24 
A patient requests the test and insists on 
having it done 
32 (94) 2 (6)  12 (86) 2 (14) 0.57 
I hear that my colleagues are 
recommending it to their patients 
9 (27) 25 (74)  2 (14) 12 (86) 0.47 
Specialists I work with recommend 
ordering the test 
26 (77) 8 (24)  12 (92) 1 (8) 0.41 
The test is inexpensive 21 (62) 13 (38)  6 (43) 8 (57) 0.34 
The test is easily accessible 26 (77) 8 (24)  7 (50) 7 (50) 0.09 
The test is easy to administer 26 (77) 8 (24)  7 (50) 7 (50) 0.09 
The test will take less time to order than to 
convince a patient they do not need it 
14 (41) 20 (59)  5 (36) 9 (64) 1.0 
†p-values comparing Screeners and Non-Screeners’ screening practices for categorical variables 
assessed by Fisher’s exact test due to frequent small expected cell sizes. 
Number of responses to a specific statement within the groups may not sum to group total due to 
missing values. 
Percentages may sum to more than 100% due to rounding. 
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3.7  Influence of Lung Cancer in Self or Close Relative 
and Smoking on Screening Behaviour 
Table  3-7 reports the influence of a lung cancer diagnosis for physician personally or for 
someone close or of smoking status on screening behaviour (Questionnaire Section V, 
questions 1-3).  
There were no statistically significant differences between Screeners and Non-Screeners 
in the proportion who had experienced a diagnosis of lung cancer themselves or anyone 
close to them. This response could not be further assessed by smoking status since 29 out 
of 51 participants answered both questions as smoker and as non-smoker and as such 
could not be clearly assigned as either smoker or non-smoker. 
Table  3-7 Close experience with lung cancer and smoking status 
 All 
participants 
N = 49 
Screeners 
n = 34† 
Non-
Screeners 
n = 15† 
p-value‡ 
Have you or anyone close to 
you ever been diagnosed with 
lung cancer? n (%) 
    
Yes 13 (27) 11 (32) 2 (14) 0.29 
No 35 (73) 23 (68) 12 (86)  
     
Would seek screening for self, 
n (%) 
    
     
Yes 5 (11) 5 (15) 0 (0) 0.30 
No 41 (89) 28 (85) 13 (100)  
†Participants within columns may not sum to n due to missing values. 
‡Fisher’s exact test  
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3.8 Influence of Patient Factors in Clinical Vignettes 
Table  3-8 reports the proportion of participants who indicated they would screen for each 
of the six scenarios (Questionnaire Section III). CXR was the most frequently ordered 
test. 
Table  3-8 Proportions of participants screening using CXR, CT, or sputum 
cytology in uncomplicated and complicated scenarios  
 n (%) 
CXR 
 
    Uncomplicated Scenario 
 No complications 23 (48%) 
    Complicating dynamic  
 Expectation 21 (44%) 
 Anxiety 28 (58%) 
 Family History 30 (63%) 
 Poor relationship 23 (48%) 




    Uncomplicated Scenario 
 No complications 3 (6%) 
    Complicating dynamic  
 Expectation 2 (4%) 
 Anxiety 3 (6%) 
 Family History 3 (6%) 
 Poor relationship 2 (4%) 




    Uncomplicated Scenario 
 No complications 9 (19%) 
    Complicating dynamic  
 Expectation 6 (13%) 
 Anxiety 5 (10%) 
 Family History 7 (15%) 
 Poor relationship 6 (13%) 
 All four dynamics 8 (17%) 
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3.9 Influence of Patient Factors in Clinical Vignettes 
Table  3-9 compares the proportion of participants who screened in the uncomplicated 
scenario (Scenario 1) with each of the complicated scenarios (Scenario 2 – 6). The 
purpose of the analysis is to determine if the factor(s) introduced in each scenario 
significantly affects the decision to order each lung cancer screening test. The p-value 
shown indicates if there is a statistically significant effect due to the introduction of this 
factor. It is computed using the McNemar test for matched pairs of data, in this case the 
comparison of results for the uncomplicated scenario with each of the complicated 
scenarios. Note that participants are not divided into the previous Screener/Non-Screener 
categories. The table divides participants into two groups, those who screened in the 
uncomplicated scenario and those who did not. Within each group, results are further 
subdivided into those who would/would not screen to make it easier to see changes in 
behaviour between the scenarios and groups.  
A walkthrough will be presented to make this clearer. The first set of yes and no values 
indicate that 23 participants said they would screen using a CXR in the uncomplicated 
scenario (Scenario 1), while 25 participants said they would not. So based on this 
response, the respondents were divided in two groups; Uncomplicated Screeners and 
Uncomplicated Non-Screeners. 
We then looked at the responses of Uncomplicated Screeners to see what they would do 
in complicated scenarios. We found that if the patient expects the test, 15 of the 23 (65%) 
that did screen in Scenario 1 would also screen when the complicating dynamic 
expectation was added (Scenario 2), while 8 (35%) would not. 
Similarly, among the 25 participants who indicated they would not screen in the 
uncomplicated situation, 6 (24%) now would screen when the patient expects the test as 
in Scenario 2. However, 19 participants (76%), did not change their position and would 
not screen whether the patient expected the test or not. 
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So the question is, does adding the dynamic of expectation to the patient- physician 
interaction change the proportion of participants who would screen? To assess this, our 
interest is in those who change their screening decisions between the two scenarios. On 
the left hand side we see that, when we add the element of expectation (Scenario 2), 8 of 
the 23 participants (35%) who would have screened in Scenario 1 choose not to screen 
with a CXR in Scenario 2, while 6 of the 25 participants who would not have screened in 
Scenario 1 (right side), choose to screen in Scenario2. The McNemar statistic examines 
the difference in the choices made in each of these scenarios. In case of Scenario 2 versus 
Scenario 1, there is no statistically significant change in choices (p-value=0.79. As such 
we can draw no overall conclusion about the impact of patient expectation on screening 
decisions – in some it appears to decrease the tendency to screen, while in others it seems 
to increase it. 
Similarly, the results do not show a statistically significant change with the addition of 
complicating dynamics of anxiety, family history or poor relationship are added as 
individual complicating dynamics in each of the scenarios. We do however, find the 
results to be clinically relevant as 40% participants who did not screen in Scenario 1 
indicated they will screen if positive family history was added (Scenario 4) 
Results show a statistically significant difference for participants’ responses in the 
uncomplicated scenario (Scenario 1) compared to responses for the multiple dynamic 
scenario (Scenario 6) p-value=0.006. 
There is no statistically significant indication that FPs will change their screening 
practices with chest CT or sputum cytology when the dynamics of patient expectation, 
patient anxiety, family history, or poor patient-physician relationship are present 
compared to when they are not.  Overall it appears that FPs are generally unlikely to 
screen ever-smokers with chest CT under any scenario situations. 
   
   
Table  3-9 Comparison of the proportions of participants screening using CXR, CT, or sputum cytology in 
uncomplicated versus complicated patient-physician interactions 
CXR  Screen in uncomplicated scenario   
 Yes, n = 23 (48%)  No, n = 25 (52%)  
 Screen in complicated scenario  
Complicating dynamic Yes No  Yes No p-value* 
       
Expectation 15 (65%) 8 (35%)  6 (24%) 19 (76%) 0.79 
Anxiety 21 (91%) 2 (9%)  7 (28%) 18 (72%) 0.18 
Family History 20 (87%) 3 (13%)  10 (40%) 15 (60%) 0.09 
Poor relationship 18 (78%) 5 (22%)  5 (20%) 20 (80%) 1.0 
All four dynamics 21 (91%) 2 (9%)  14 (56%) 11 (44%) 0.006 
       
       
CT Chest Screen in uncomplicated scenario  
 Yes, n = 3 (6%)  No, n = 45 (94%)  
 Screen in complicated scenario  
Complicating dynamic Yes No  Yes No p-value* 
       
Expectation 1 (33%) 2 (67%)  1 (2%) 44 (98%) 1.0 
Anxiety 2 (67%) 1 (33%)  1 (2%) 44 (98%) 1.0 
Family History 2 (67%) 1 (33%)  1 (2%) 44 (98%) 1.0 
Poor relationship 1 (33%) 2 (67%)  1 (2%) 44 (98%) 1.0 
All four dynamics 1 (33%) 2 (67%)  7 (16%) 38 (84%) 0.18 
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Sputum cytology Screen in uncomplicated scenario  
 Yes, n = 9 (19%)  No, n = 39 (81%)  
 Screen in complicated scenario  
Complicating dynamic Yes No  Yes No p-value* 
       
Expectation 5 (56%) 4 (44%)  1 (3%) 38 (97%) 0.38 
Anxiety 5 (56%) 4 (44%)  0 (0%) 39 (100%) 0.13 
Family History 5 (56%) 4 (44%)  2 (5%) 37 (95%) 0.69 
Poor relationship 4 (44%) 5 (56%)   2 (5%) 37 (95%) 0.45 
All four dynamics 7 (78%) 2 (22%)  1 (3%) 38 (97%) 1.0 
*McNemar’s test comparing the proportion of participants who would screen in the uncomplicated scenario to the 
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3.10 Proportion of participants screening within each 
scenario by perception of screening 
recommendation 
Table  3-10 reports on the influence of perception of screening guideline 
recommendations on screening decision making. For this analysis, the significant p-value 
was set at 0.008 to account for multiple testing. In scenarios where the patient-physician 
interaction was uncomplicated, patients expected the test, or patients had a family history 
of disease, participants were statistically significantly more likely to screen with a CXR if 
they perceived that it was recommended than if it was not. Recommendations did not 
clearly change screening practice if the patient was anxious, had a difficult relationship 
with the physician, or had multiple dynamics, as participants who did not perceive the 
test as recommended often showed some tendency to screen under these conditions. 
From the group of FPs who did not perceive CXR was recommended and did not screen 
(21), a clinically significant number of them were influenced to screen if the patient was 
anxious or there was a positive family history of disease (for each factor, an increase 
from 8 to 13 out of 21, 63%) and with multiple dynamics (an increase from 8 to 19 out of 
21, 138%).  
So we can conclude that perception of recommendations influences FPs decision-making 
for lung cancer screening with CXR. However, when faced with patient factors of 
anxiety, difficult relationship and multiple complicating factors FPs decision to screen 
over-rides their perception meaning that these factors influence their decision-making. 
Perception of recommendation regarding screening with CT did not appear to make a 
difference as to whether participants would screen or not. Although 7 individuals 
indicated that they felt CT is recommended as a screening tool in ever-smokers, its use 
was infrequently indicated in the scenarios. 
Perception of recommendation regarding screening with sputum cytology appeared to 
make a difference in all scenarios as to whether or not a FP decided to screen. In each 
scenario approximately half to two-thirds of the nine FPs who felt that screening with 
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cytology in ever-smokers is recommended indicated that they would screen, while less 
than 10% of those who felt that cytological screening was not recommended, indicated 
they would order it. This contrast was statistically significant in all comparisons 
regardless of the presenting dynamic.  
 
   
   
Table  3-10 Proportion of participants screening within each scenario by perception of screening recommendation 
 
Overall N=48*   
CXR   
Perceived as  
recommended, n=18 




 Screen, n (%) Screen, n (%) Screen, n (%)  
 Yes No Yes No Yes No  
Uncomplicated 23 (48) 25 (52) 14 (78) 4 (22) 8 (28) 21 (72) 0.001 
Expectation 21 (43) 27 (57) 14 (78) 4 (22) 7 (24) 22 (76) 0.001 
Anxiety 28 (58) 20 (42) 14 (78) 4 (22) 13(45) 16 (55) 0.04 
Family history 30 (62) 18 (38) 16 (89) 2 (11) 13 (45) 16 (55) 0.005 
Poor relationship 23 (48) 25 (52) 12 (67) 6 (33) 10 (34) 19 (66) 0.04 
All four dynamics 35 (73) 13 (27) 15 (83) 3 (17) 19 (66) 10 (34) 0.32 
     
 Overall N = 48*   
Chest CT 
  
Perceived as  
recommended, n=7 




 Screen, n (%) Screen, n (%) Screen, n (%)  
 Yes No Yes No Yes No  
Uncomplicated  3 (6) 45 (94) 1 (14) 6 (86) 2 (5) 38 (95) 0.39 
Expectation 2 (4) 46 (96) 0 (0) 7 (100) 2 (5) 38 (95) 1.0 
Anxiety 3 (6) 45 (94) 1 (14) 6 (86) 2 (5) 38 (95) 0.39 
Family history 3 (6) 45 (94) 1 (14) 6 (86) 2 (5) 38 (95) 0.39 
Poor relationship 2 (4) 46 (96)  1 (14) 6 (86) 1 (3) 39 (97) 0.28 
All four dynamics 8 (17) 40 (83) 2 (29) 5 (71) 6 (15) 34 (85) 0.59 
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 Overall N = 48*   
Sputum cytology 
  
Perceived as  
recommended, n=9  




 Screen, n (%) Screen, n (%) Screen, n (%)  
 Yes No Yes No Yes No  
Uncomplicated  9 (19) 39 (81) 6 (67) 3 (33) 3 (8) 36 (92) 0.0005 
Expectation 6 (12) 42 (88) 5 (56) 4 (44) 1 (3) 38 (97) 0.0004 
Anxiety 5 (10) 43 (90) 4 (44) 5 (56) 1 (3) 38 (97) 0.003 
Family history 7 (15) 41 (85) 5 (56) 4 (44) 2 (5) 37 (95) 0.001 
Poor relationship 6 (12) 42 (88) 6 (67) 3 (33) 0 (0) 39 (100.0) <0.0001 
All four dynamics 8 (17) 40 (83) 6 (67) 3 (33) 2 (5) 37 (95) 0.0002 
*One participant did not provide a response to the vignette questions; among the remaining 48, two did not state their 
perception of CXR and CT respectively in ever-smokers;  
†p-values from Fisher’s exact test due to frequent small expected cells sizes and α = 0.008 to compensate for multiple 
comparisons (0.05/6 scenarios). 
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3.11 Conclusions 
Results showed a substantial variation in reported lung cancer screening behaviour 
among FPs. Participants were classified as Screeners (69%) or Non-Screeners (31%) 
based on whether or not they reported ordering screening tests for their asymptomatic 
ever-smoker patients. Among Screeners, 16 of the 34 FPs (47%) also screened never-
smokers.  
Screeners were more likely to work more hours per week than Non-Screeners but were 
otherwise not distinguishable with respect to gender, age, College Certification or 
membership, type of practice, practice location or teaching affiliation. 
Despite the fact that national guidelines did not recommend CXR as a screening test, it 
was the most frequently ordered test. 
Missing a case of lung cancer resulted in increased screening behaviour for some time 
afterwards in both Screeners (85%) and Non-Screeners (50%). Similarly, a positive 
family history of lung cancer, occupational exposure such as asbestos, silica and 
chemicals or presence of comorbid conditions such as COPD resulted in a statistically 
significant difference in screening behaviour in Screeners (67%) and Non-Screeners 
(21%). 
A minority of Screeners (13%) and a majority of Non-Screeners (79%) did not 
recommend CXR for screening because they thought there was potential to cause more 
harm than good. Medico-legal considerations had no impact on screening behaviour 
among FPs in either group. 
Both Screeners and Non-Screeners were equally likely to apply lung cancer screening 
guidelines to each individual patient’s context. 
Screening behaviour was influenced in favour of screening if the test was easily 
accessible or if the test was easy to administer, Screeners (77%) and Non-Screeners 
(50%). 
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Thirty-nine percent of FPs perceived CXR was recommended for lung cancer screening 
even though the prevailing guidelines at the time of data collection did not recommend 
CXR as a lung cancer screening test. It is interesting to note that both Screeners and Non-
Screeners found the guidelines for lung cancer screening for asymptomatic ever smokers 
to be unclear. 
It is worth noting that 18 participants thought CXR was recommended, but when faced 
with a scenario, 23 actually ordered one. Their responses changed when the question was 
one about recommended guidelines or a hypothetical case scenario suggesting that patient 
factors are a major influence on FP screening decision-making behaviour.  
The fact that 48% screened in the uncomplicated scenario contrary to prevailing national 
guidelines, suggests that there must be other factors (besides the complicating dynamics 
assessed in this study) influencing their decision-making. 
Among the participants who would not screen in the uncomplicated scenario, some 
indicated they will screen in the presence of  additional factors (expectation, anxiety, 
family history, poor relationship) indicating that these factors influence their decision-
making.  
FPs’ decision making is influenced by their perception of guidelines, however the 
presence of certain patient factors over rides their perception and influences their 
decision-making. 
 





This study made several important findings regarding the lung cancer screening practices 
and decision-making of family physicians (FPs) practicing in urban and rural 
Saskatchewan. First, the results showed a substantial variation in the reported lung cancer 
screening behaviour of FPs, both in their decision to screen and choice of screening test, 
with a majority of participants reporting they screened for lung cancer. Second, chest X-
ray (CXR) was the most commonly ordered screening test. Third, based on whether or 
not they reported ordering screening tests for their asymptomatic ever-smoker patients, 
69% were classified as Screeners. Fourth, clinical decision-making was assessed via 
clinical vignettes; the results demonstrated that up to 73% of FPs would order CXR for 
screening, contrary to prevailing guidelines. A significant number of FPs indicated they 
would screen in response to multiple patient factors (expectation, anxiety, family history, 
poor patient-physician relationship) in contrast to an uncomplicated patient scenario. This 
was true even for FPs who had indicated in another question that they perceived the 
guidelines to be against screening.  
This study is unique, the first study regarding lung cancer screening in Canada. It 
contributes to the literature about existing FPs’ practices and decision-making regarding 
lung cancer screening and highlights implications to health care cost, patient care, CME 
initiatives, and clinical practice guidelines. 
4.2 Physician Factors and Screening Behaviour 
Screeners were more likely to work more hours per week than Non-Screeners but were 
otherwise not distinguishable with respect to sex, age, college certification or 
membership, type or location of practice, teaching affiliation or number of years of 
practice. This is similar to what Tudiver et al found,2,53 in that all of the above-mentioned 
factors did not significantly influence primary care physicians’ (PCPs) screening 
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decisions for breast, colorectal and prostate cancer. However, recent studies on lung 
cancer screening by PCPs found increased screening was associated with physicians 
having more than 10 years in practice in one study9, and in another more than 20 years39. 
A larger sample size might demonstrate similarities or differences between Screeners and 
Non-Screeners, thereby permitting further comparison with the findings of other studies.  
4.3 Influence of Physician Attitudes on Screening 
Behaviour 
Some statistically significant differences were found between Screeners and Non-
Screeners when asked if they would screen in the presence of potentially influential 
physician or patient factors (one factor per question).  
Screeners were more likely to be influenced to screen than Non-Screeners by one 
physician factor and by three patient factors.  Missing a case of lung cancer influenced 
FPs stated behaviour to increase screening. This result is consistent with the influence of  
this physician factor in Tudiver`s qualitative study10 for other cancers. Similarly, positive 
family history, occupational exposure such as asbestos, silica and chemicals, and the 
presence of comorbid conditions such as COPD resulted in increased screening 
behaviour. These patient factors consist of known risks for developing lung cancer other 
than by smoking.7 The positive influence of these factors on screening can be explained 
by Screeners using evidence-based decision making for a population at risk (ignoring 
issues surrounding choice of screening test).  
Non-Screeners (79%) were more likely than Screeners (13%) to not recommend CXR for 
screening due to the belief that it had the potential to cause more harm than good. The 
strong influence for Non-Screeners is consistent with evidence-based decision making 
informed by risk of potential harm.7 This  physician factor is consistent with its 
identification by Tudiver10. However, it was found to have a relatively weak screening 
influence for screening using PSA and mammograms in Tudivers’ survey.53 
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4.4 Physicians’ Perception of Lung Cancer Screening 
Guidelines 
Screeners were more likely (52%) than Non-Screeners (7%) to perceive that CXR was 
recommended for their smoker patients. Yet, there are no guidelines, which recommend 
use of CXR as screening test under any patient conditions. It is interesting to note that 
both Screeners (69%) and Non-Screeners (46%) found the guidelines for lung cancer 
screening for asymptomatic ever smokers to be unclear. The results of this study 
demonstrate wide variation in lung cancer screening practices between FPs and frequent 
ordering of tests not recommended in national guidelines. It is important to address this 
variation as well as other guideline discordant practices as they have significant, 
unnecessary clinical and cost implications.69-71 As an example, guideline discordant care 
for lung cancer in elderly patients results in poor survival outcomes.72 Unnecessary tests 
may cause avoidable radiation exposure and anxiety that may be induced by false 
positive results.7 
In part, these results imply a gap in knowledge with respect to lung cancer screening 
guidelines. The survey item which collected these data directly measured perception, not 
knowledge. It was not possible to know in advance which of potentially many 
guideline(s) the respondent was informed by, so direct questioning about knowledge of a 
specific guideline or guidelines would be premature and outside the scope of the study. 
Asking about perception also avoided potential risk of non-response if a participant felt 
he/she was being tested/assessed on specific guideline knowledge. None the less, even 
though the survey item measured perception, it also indirectly measured knowledge, 
finding some knowledge gaps with respect to related parts of a specific guideline. This 
was true for the perception that guidelines recommended CXR for smoker patients, when 
no major guidelines did so. This finding highlights one significant gap, but are there 
others? More comprehensive research, measuring detailed knowledge of specific 
guidelines would be valuable and necessary to find all the gaps. They could then be 
addressed by revised guidelines, arranging CME training, or publishing guidelines in 
journals. To allow access and wider dissemination, guidelines for lung cancer screening 
can be made part of the electronic medical record (EMR).44 
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Future research should explore why FPs order CXR as a screening test, especially among 
those who perceived guidelines did not recommend using CXR as a lung cancer 
screening test. This could be achieved by conducting qualitative research, either in-depth 
interviews or focus groups. 
Both Screeners and Non-Screeners were equally likely to state that they apply lung 
cancer guidelines to each individual patient’s context consistent with findings in 
literature.73,74 
4.5 Choice of Screening Test among Screeners 
Screeners comprised 69% of FPs. Among these Screeners, 47% also screened never-
smokers.  
CXR was the most frequently ordered lung cancer screening test, reported by 67% of 
FPs, despite the fact that national guidelines did not recommend CXR for this purpose. 
This was confirmed by the results from clinical scenarios with multiple dynamics 
(Scenario 6), where 35 out of 48 FPs (73%) said they would screen using CXR. This 
seems to indicate a higher prevalence than reported in a prior U.S. study, which utilized a 
survey questionnaire to measure attitudes, beliefs and behaviour for lung cancer 
screening. It concluded that a substantial number of physicians (amongst FPs and 
pulmonologists) reported they screen for lung cancer using CXR (25%) despite the fact 
that it was not recommended.9  
The question about why FPs order CXR screening tests remains unanswered. Since a 
surprisingly large number of participants indicated they screen using CXR in this study, 
further research to identify the factors that influence decision- making for lung cancer 
screening should be conducted. A qualitative research design can explore this in future. 
This knowledge will help to address the frequency of its use as it results in unnecessary 
investigations and has unnecessary cost implications69,70 without any return in improved 
health care delivery. 
  52 
 
4.6 Influence of Non-medical Factors on Screening 
Behaviour 
Screening behaviour was influenced in favour of screening if the test was easily 
accessible or if the test was easy to administer. This finding did not reach statistical 
significance but was a clinically relevant difference that in a larger sample may have been 
significant. This finding may help to shed some light on why FPs did not report ordering 
a CT scan and sputum cytology at a high frequency. It might be that CXR was the most 
ordered screening test because of its availability at most rural, regional and urban sites. 
CXR might also be ordered as a baseline comparison reference, believed to be an 
inexpensive way to detect potential lung cancer via abnormal changes in subsequent 
images.5 CT Scanners are not available in rural facilities and radiologists at regional sites 
may refuse tests for screening purposes because of staffing issues or may triage as a CT 
that can be done several months later. It may also be that FPs offer CT chest as a 
screening test but patients refuse it to avoid driving or because some of them may be 
dependent on family members living at remote sites. As well, sputum cytology may yield 
high false negative tests and it may be that FPs consult pulmonologists for bronchoscopy 
and sputum cytology instead of ordering it themselves. 
4.7 Influence of Lung Cancer in Self or Anyone Close 
and Smoking Status on Screening Behaviour 
There were no statistically significant differences between Screeners (32%) and Non-
Screeners (14%) based on themselves or close relatives having lung cancer on screening 
behaviour. These results are consistent with the Tudiver survey53 which did not report 
significant influence. Note that this physician factor was represented in the current study 
population, reported by (27%) participants, with the larger proportion being Screeners. A 
larger sample size might demonstrate similarities or differences between Screeners and 
Non-Screeners. 
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4.8 Influence of Patient Factors in Clinical Scenarios 
Section III of the survey consisted of the vignette-based study, which explored 
participants’ intended behaviour under the influence of patient factors also called 
complicating scenarios. The outcome was the decision to order one or more types of lung 
cancer screening tests in each scenario. The goal was to discover the influence of these 
factors on FPs’ decision-making.  
Results for clinical scenarios for the baseline uncomplicated scenario (Scenario 1) 
showed 48% of participants would order a CXR to screen for lung cancer. The results 
showed a statistically significant increase in the screening behaviour in the presence of 
multiple patient factors (Scenario 6 – all four dynamics) p=0.006. When positive family 
history was added as complicating factor, the results showed a clinically relevant increase 
in CXR screening behaviour. Only a larger study would determine whether these trends 
are statistically significant.  
On the other hand, non-screeners in the uncomplicated scenario showed a tendency to 
increase screening in each complicated scenario with statistical significance found when 
all four dynamics were in play. The non-screeners in the uncomplicated scenario seem to 
be leaning toward screening when complicating dynamics are added while the screeners 
in uncomplicated scenario leaned in the opposite direction. Only a larger study would 
determine whether these trends are statistically significant. If they are, further qualitative 
research might address the differences in approach to their practice. 
There were no statistically significant indications that FPs will change their screening 
practices with chest CT or sputum cytology when the dynamics of patient expectation, 
patient anxiety, family history, or poor patient-physician relationship are present 
compared to when they are not.  Overall, it appears that FPs were generally unlikely to 
screen ever-smokers with chest CT under any scenario. It is interesting to note, however, 
that only approximately half of the nine participants who would have screened using 
sputum cytology in the uncomplicated scenario would not do so in more complex 
situations. Further research might explore the rationale behind this observation. 
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FPs were more likely to make decisions according to their perception of guidelines as 
was observed in the responses for the uncomplicated scenario (Scenario 1) and in the 
presence of patient expectation (Scenario 2) and family history (Scenario 3) for CXR and 
in all complicating scenarios for sputum cytology. However, the presence of certain 
patient factors in the simulated clinical scenarios (patient anxiety, poor patient-physician 
relationship and multiple dynamics) influences their decision-making over-riding their 
perception of guidelines. 
These findings are consistent with the results of Haggerty et al2 who found that decision-
making by some FPs, who normally followed evidence-based practice (guideline 
perception) was overridden in the presence of influential patient factors. Decision-making 
was influenced by patient anxiety or expectation for the cancers they studied (breast, 
colon and prostate). This study of lung cancer screening decision-making demonstrated 
this phenomenon for multiple patient factors (patient anxiety, expectation, positive family 
history, poor patient-physician relationship).  
The notion that patient factors may lead FPs to override their decision to follow 
guidelines is further supported by other findings of this study. When asked in a single-
item opinion-based question if CXR is recommended for lung cancer screening, 18 
participants responded that they perceived that CXR was recommended; yet, when faced 
with an uncomplicated patient scenario, 23 indicated they would order a CXR. The fact 
that 48% screened in the Uncomplicated Scenario contrary to prevailing national 
guidelines, suggests that there must be other factors (besides the complicating factors 
assessed in this study) influencing their decision-making. In summary, presence of 
multiple factors (patient anxiety, expectation, positive family history of lung cancer, poor 
patient-physician relationship) significantly influenced FPs decisions to screen and over-
rides their perception of guidelines. These findings illustrate the influence of patient 
factors on evidence-based medicine for lung cancer screening decision-making. 
Makers of clinical practice guidelines should consider patient context to formulate better 
guidelines. Recent research promotes incorporating patient preferences and context into 
the guideline development process and are easy to use for physicians.73 Patient 
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preferences and context are essential to shared decision making. The level of compliance 
depends on patient involvement and consideration of their specific context highlighting 
the need to improve the guideline development process. Strong recommendations are 
discouraged where the best decision depends on patient factors – preferences, context, 
goals, values.75  
The high self-reported prevalence in single item questions and measured inclination to 
screen in clinical scenarios using CXR needs to be addressed. These findings on lung 
cancer screening decision-making should be of considerable interest in the current culture 
of health care cost reduction, for example, the Choosing Wisely Canada76 campaign 
encouraging patient-physician dialog about unnecessary tests, treatments and procedures. 
4.9 Implications 
The study findings on FPs’ lung cancer screening decision-making suggest the following 
important clinical implications: 
1. Ordering of CXRs, which is against evidence-based guidelines adds unnecessary 
costs and burden on the health care system. 
2. Guideline discordant investigations and false positive tests cause anxiety thereby 
increasing morbidity and further exposure to radiation with more investigations 
and consultations without any benefit to the patient. 
3. Lack of knowledge of guidelines leads to variation in practice, highlighting the 
need for wide dissemination of evidence-based guidelines by CME, and/or 
integration within an EMR. 
4. Various strategies in guideline development such as incorporating patient 
preferences, and engagement of patient values and preferences in decision-making 
may be employed to implement guidelines.44,73,74,77-84  
5. The need for guideline makers and those implementing quality improvement 
strategies that measure adherence to guidelines to recognize that some variability 
is to be expected.73,74 
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4.10 Strengths 
The study made use of evidence that incorporating a clinical vignettes design is a 
preferred methodology to assess physician behaviour and decision-making in surveys. 
Single-item questions responses are subject to recall bias and do not allow behaviour 
assessment in varying patient-specific contexts which are observed in routine clinical 
encounters. A clinical vignette methodology allowed simulating real life clinical 
encounters and permitted studying FP’s intended behaviour in the presence of varied 
patient factors. Clinical vignettes have been  shown to be a valid and cost-effective 
method to assess physician clinical decision-making, including those in cancer care.85-88 
Peabody85 concluded that clinical case vignettes appear to be a valid and comprehensive 
method to focus on actual clinical practice in an outpatient setting, rather than physician 
competence. That study ranked the relative effectiveness of assessing clinical decision-
making as 1) standardized patients, 2) clinical case vignettes and 3) chart abstraction. 
Research, specifically on vignette-based surveys88 demonstrated they were more time 
efficient than record reviews or using standardized patients, and more cost-effective than 
standardized patients to assess clinical decision-making. Thus, the current survey that 
included clinical scenarios used the best evidence-based methodology available. 
4.11 Limitations 
The study has the following known limitations: 
1. The ability to generalize to all FPs in Saskatchewan is limited by the low response 
rate. It is not possible to know if the sample was representative of the screening 
behaviour of the provincial population of FPs. However, it did appear that FP 
characteristics in our sample were comparable to provincial and Canadian FPs. 
2. The study was limited to FPs in Saskatchewan, so the results may not reflect 
behaviour of all Canadian FPs. 
3. The sample size was small making it difficult to detect clinically relevant 
differences. Statistical significance may not have been seen for many analyses 
because the sample size was relatively small and for repeated measures, the 
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Bonferroni adjustment was a strong correction to the p-value. However, there 
appeared to be clinically relevant trends and additional significance might be seen 
with a larger sample size.  The proportions are susceptible to changes with small 
variation in the allocation of participants, again due to small sample size. 
4. The results are based on FPs’ reported behaviour and may be subject to 
desirability bias. Further research might be done to validate self-reported data, for 
example by comparison with chart audit of medical records.  
5. The survey design can explore behaviour but not reasons behind the behaviour. 
Future qualitative study can address this concern. 
4.12 Direction for future research 
The results of the present study emphasize the need to better understand reported lung 
cancer screening behaviour and decision-making suggesting four potential research 
studies.  
1. Research to examine why FPs screen patients for lung cancer and why they order 
CXR as a screening test. This research would examine the factors identified in 
this study and any additional factors that influence FPs’ lung cancer screening 
decision-making. This could be achieved by conducting qualitative research, 
either in-depth interviews or focus groups. 
2. After exploring qualitatively the factors influencing FPs' lung cancer screening, a 
national Canadian survey of FPs regarding their behaviour and decision-making 
for lung cancer. 
3. Research to assess FPs’ actual lung cancer screening behaviour by chart audit to 
address desirability bias and recall bias in self-reported behaviour in surveys. 
4. Research to explore how guideline makers might engage FPs in the development 
of guidelines in the context of family practice. The results may then be used to 
inform guideline makers so that they can address concerns raised by their users. 
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Letter of Information 
Lung Cancer Screening Practices of Family Physicians in 
Saskatchewan 
Introduction and Purpose of Study: 
You are invited to participate in a study to explore your ideas, thoughts and experiences as 
a practicing family physician in Saskatchewan. The purpose of this letter is to provide you 
with the information you require to make an informed decision on participating in this 
research. 
Who Can Participate: 
You are invited to participate in this research if you are a practicing family physician in 
Saskatchewan. In order to be eligible to participate you must be between the ages of 25-
65. 
What Will the Study Involve: 
Phase I of the study is a census survey to explore lung cancer screening practices.  
In Phase II of the study, you may be invited to participate in an individual interview. The 
interview will take place at a location and time that is convenient for you and will take 
approximately thirty to forty-five minutes. The interview will be audio taped and 
transcribed verbatim.  
Confidentiality and Privacy: 
All information for the study is confidential. Each participant is assigned an ID number. 
All participant identifiers and ID numbers will remain in a master list in a password-
protected database. The master list will remain separate from the data. The master list 
linking participant names to identifiers will be held separately from the data set and 
password protected or locked in a separate location (hard copy). The voice file of the 
interview will be sent off-site to a professional transcriptionist to be transcribed verbatim. 
If you use any names during the interview, they will be not transcribed but simply 
replaced with the word "name" or "place" (e.g. John = "name"). All electronic files will be 
password protected. All hardcopy forms and transcripts will be stored in a locked filing 
cabinet for security. 
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Voluntary Participation: 
Participation in this study is voluntary. You may refuse to participate, refuse to answer any 
questions or withdraw from the study at any time. 
Risks and Benefits: 
We see no risks associated with this research. The benefits include gaining a better 
understanding of the challenges you face regarding screening decisions for lung cancer 
and to influence improvements in this aspect of practice. 
Do You Have Questions: 
If the results of the study are published, your name will not be used and no information 
that discloses your identify will be released or published without your explicit consent to 
the disclosure. 
If you have any questions about your rights as a research participant or the conduct of the 
study, please contact Dr. David Hill, Scientific Director, Lawson Research Institute at 
(###) ###-####. Representatives of The University of Western Ontario Health Sciences 
Research Ethics Board may require access to your study-related records or may follow up 
with you to monitor the conduct of the research. 
If you have any questions regarding your participation in this study, please contact Dr. 
John Feightner, Principal Investigator at (###) ###-#### 
Thank you for your consideration. 
Dr. John Feightner 
Professor 
 
Dr. Judith Belle Brown 
Professor 
 
Centre for Studies in Family Medicine  
Department of Medicine 
Schulich School of Medicine & Dentistry 
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Appendix C  
Analysis of Tudiver Survey Instrument 
C.1 Analysis 
The sample questionnaire, appended to this discussion, was provided by Dr Tudiver53 for 
review. It has the following structural attributes.  
1. Section I – Questions about perceptions of current cancer screening guidelines 
2. Section II – Questions about which factors influence cancer screening decisions 
3. Section III – Clinical vignettes (two vignettes/cancer screen, six total) to inquire 
about decision to order cancer screening tests with variations in 4 patient factors 
4. Section IV – Questions about respondent physician and practice characteristics 
5. Section V – Questions about respondents personal experience with cancer and 
cancer screening  
Note that the literature53 refers to a two-part survey, where Part 1 includes Sections I, II, 
IV and V and Part 2 includes Section III. A fractional factorial design ensured that each 
physician received a unique questionnaire – Part 1 was common to all questionnaires but 
Part 2 was unique. Part 2 of the sample questionnaire had the following notable features: 
1. Two prostrate cancer screening vignettes, males only, alternated good/bad 
patient/physician relationship 
2. Two breast cancer screening vignettes, females only, alternated good/bad patient 
physician relationship 
3. Two colorectal cancer screening vignettes, female, male, alternated good/bad 
patient physician relationship 
4. The structure of each vignette modelled the flow of information/activity in a 
clinical encounter. In addition, the style of writing employed expressed the level 
of each of the four patient factors being investigated in a clinically meaningful 
manner. Sequentially,  patient/physician relationship factor was explained first, 
then reason for the patients visit with relevance to specific cancer screening, then 
medical history factor (personal, family, risk factors), then patient factors 
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(expectation of screening test, significant anxiety) and then asymptomatic clinical 
examination results.  
Overall, Section III implemented a fractional, factorial design with six clinical scenarios, 
each representing a frame (which set the context) and each having 16 variations 
representing all possible combinations of the four patient factors (independent variables). 
Six frames implies 6 x 16 = 96 vignettes were required in the end and many more written 
during the iterative development/edit phase. The fractional factorial design required the 
unique series always had one vignette with all patient factors present, one with no patient 
factors present, and a random variation in patient factors in the remainder. The vignettes 
were presented in random order to minimize sequence bias. It appears that the frame 
position was fixed (Scenario #1-#6) so randomness must have been introduced by which 
patient factor combination would appear in which frame. 
The clinical case vignettes were developed and tested in 4 steps. 
1. Initially authored by the clinical investigators based on their experience. 
2. Submitted to 12 family physicians colleagues for empirical review of 
descriptions. 
3. Minimum of 9/12 (75%) had to correctly identify the intended level of each 
patient factor, else modified or replaced. 
Those requiring correction were submitted to another set of 12 physicians to filter again 
according to 75% rule above. 
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Appendix D  
Tudiver Survey Instrument 
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Appendix E  
Detailed Methods for Questionnaire Development 
E.1 Questionnaire Design Methodology 
The following describes the approach taken to develop this study’s survey instrument, a 
questionnaire adapted from the Tudiver et al. survey tool. The Tudiver et al. study 
explored factors that influence cancer screening decision-making for prostate, breast and 
colorectal cancer. Since the current study objectives were focussed specifically on lung 
cancer screening, the methodology used in this study was unique.  
The Tudiver et al. survey instrument was adapted to fulfil the new study objectives. Their 
survey tool had questions on prostate, colorectal and breast cancer. They were replaced 
with questions specifically about lung cancer screening. Questions were also added to 
estimate the proportion of physicians screening by self-report and to identify which tests 
were preferred.  
E.2 Questionnaire Items 
The questionnaire developed for this study was a derivation of the validated survey 
instrument used by Tudiver et al.2,10,53 with modifications to adapt it to study how family 
physicians make lung cancer screening decisions. The questionnaire is composed of 38 
single item questions (some with multiple answer subparts) and six clinical case 
vignettes, organized into five sections: 
I. Physician perceptions of guidelines for lung cancer screening; 
II. Inquiry into which medical and non-medical factors influence the participating 
physician’s lung cancer screening decisions; 
III. Clinical case vignettes to  study the influence of factors (patient anxiety, 
expectation, positive family history) on family physicians lung cancer screening 
behaviour; 
IV. Practice characteristics and physician demographics; 
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V. Physician’s personal experiences with lung cancer and  lung cancer screening 
behaviour; 
VI. Survey Evaluation to obtain respondent feedback on validity and reliability. 
E.2.1 Section II Items to classify physicians as Screeners or Non-
Screeners 
The survey collected data needed to classify participants into two groups – Screeners and 
Non-screeners. Direct query was chosen to minimize error and introductory questions 
(Section II, Q1 and Q2) were developed to examine screening behaviour. The following 
discussion references the actual questionnaire attached as an appendix.  
Questions 1 and 2 are identical except they address screening behaviour for two groups, 
non-smokers and current or past smokers. This broadens the survey to include screening 
behaviour towards non-smokers who sometimes develop lung cancer. Non-smokers are 
defined as patients who have never smoked. Current or past smokers are patients who 
currently smoke or have past history of smoking. 
Questions 1a and 2a are  ratio scale89 questions. The data they provide have a true zero 
value and were treated as ratio data. We are soliciting ratio data with what appears to be 
an ordinal scale with response options presented in ranges. Ranges are presented because 
it’s faster for the respondent to answer the question, lowering respondent burden. Less 
respondent burden will promote a higher rate of return which enhances the external 
validity of the study.  
Question 1b and 2b are nominal scale89 questions added to collect data on ordering 
behaviour for all types of lung cancer screening tests.  
Question 3-14 are ratio –scale questions. The data they provided have a true zero value 
and were treated as ratio data. A 4-point Likert scale was used to ease data collection. 
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E.2.2 Section III Clinical Case Vignettes 
The Tudiver et al questionnaire53 made use of clinical case vignettes noting “they have 
been shown to be a useful, inexpensive, and effective method for eliciting physicians’ 
decision-making behaviour in a simulated situation”.85 Peabody concluded that clinical 
case vignettes appear to be a valid and comprehensive method to focus on actual clinical 
practice in an outpatient setting, rather than physician competence.85 Their prospective 
study ranked the relative effectiveness of the methods studied as: 
 1) Standardized patients, 2) clinical case vignettes and 3) chart abstraction. Case 
vignettes have been used to examine physicians’ practice behaviour with cancer 
patients.90-93  
Tudiver53 stated “For research purposes, the usefulness of the clinical case vignette rests 
on the ability to vary specific factors (relevant independent variables under study) from 
one vignette to another, while keeping constant the surrounding factors of the case 
presented (the frame).” The same rationale applies to the revised clinical case vignettes 
developed for the study questionnaire. 
The survey included 6 clinical case vignettes developed by one of the clinician 
investigators (NJ). The vignettes vary the patient factors (independent variable) shown in 
Table 1, with the dependent variable being a yes/no decision to order any of the three 
screening tests (CXR, CT Chest, Sputum Cytology). 
Table 1 Patient Factors Present in Clinic Vignettes 
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E.3 Reliability and Validity 
To ensure validity and to ensure appropriateness of the reading level, the survey was 
piloted on three family physicians. This was followed by an interview to improve clarity 
and comprehensiveness of the questionnaire. This feedback led to changes to two 
questions about physician demographics: age was obtained as a range instead of an actual 
age; type of practice was broadened to add Regional to existing Rural & Urban choices. 
This study also contains a section to test actual physician behaviour in a simulated 
clinical setting by means of a clinical experimental study component, consisting of 
clinical case vignettes where testing is done in the context of a controlled environment, 
one where independent variables are manipulated to examine decision-making behaviour. 
The scenarios presented are intended to model real-world clinical encounters, enhancing 
external validity. 
References on questionnaire design and quality assessment were consulted during 
questionnaire development59-68.  
To increase the external validity of the study, a high rate of return was desired. This was 
promoted in this study by applying best practices identified in the literature including 
administration of the survey using the step-wise revised Dillman Method.58 
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